Therapeutic failure reported with HIV long-acting injectables: An analysis of the FDA Adverse Event Reporting System from 2021 to 2024.

Kenneth L McCallDanielle L CabralJamie F CoghlanAshante M ConcepcionKristine E DenimarckShawn S Shalumov

Published in: HIV medicine (2024)

Our findings suggest that healthcare professionals should have a heightened awareness of potential challenges with CAB/RPV administration, including TFs and dose omissions in real-world settings.

Keyphrases

antiretroviral therapy
adverse drug
hiv positive
hiv infected
hiv testing
human immunodeficiency virus
hepatitis c virus
hiv aids
men who have sex with men
human health
emergency department
risk assessment